Bone Medical gets approval for human clinical study

THE ROADHOUSE PHARMACY: Bone Medical Ltd (ASX: BNE) has received approval to proceed with a planned human clinical study, the company announced to the Australian Securities Exchange in April 2014.

Bone Medical said the study will compare the company’s potential oral treatment for osteoporosis against a commercially available injectable osteoporosis treatment.

The study has been reviewed and approved by the Human Research Ethical Committee at the QIMR Berghofer Medical Research Institute in Brisbane, where the study is to be conducted.

Bone Medical expects the study to commence before the end of May and is anticipated to be concluded within three months.

“One of our goals when recapitalising the company in January 2014 was to advance the company’s technology and so we are very pleased that it has taken only four months to recommence the clinical studies of Bone’s orally delivered PTH,” Bone Medical chairman said in the company’s announcement to the ASX.

Bone Medical also announced that Peter Young has stepped down as CEO and director of the Company and will now be acting in a role as senior consultant and advisor.

In this capacity, Bone Medical said Young will continue to provide ongoing operational support and strategic advice to assist the company while maintaining effective continuity going forward.

Website: www.bone-ltd.com